Is btai bullish

The sentiment among institutional investors regarding BioXcel Therapeutics, Inc. (BTAI) is currently neutral to slightly bearish. Here's the analysis to support this conclusion:

1. Institutional Ownership and Sentiment:
   • As of July 11, 2024, BTAI has 166 institutional owners and shareholders holding a total of 10,038,824 shares, which represents a significant portion of the company. However, this does not necessarily indicate sentiment, as institutions can hold shares passively as part of their diversified portfolios.
   • The Fund Sentiment Score is not available, but the absence of a significant number of institutions filing 13D/G reports within the last year suggests a lack of strong positive sentiment.
2. Recent Performance and Insider Ownership:
   • The share price has experienced a significant decline from $11.38 on July 12, 2023, to $1.20 on July 11, 2024, which could be a factor in the neutral to slightly bearish sentiment.
   • Insider ownership is low, with insiders owning under 1% of the company, which may not provide a strong signal regarding institutional sentiment.
3. Public and Institutional Profit:
   • Despite the decline in share price, institutions have profited from the market cap increase of $43 million, indicating some level of positive sentiment.
   • Retail investors have reaped the most benefits after a 66% price gain, which could suggest that institutional investors are less bullish compared to retail investors.
4. Blogger Sentiment:
   • The overall sentiment among bloggers is neutral, with no clear trend of bullish or bearish predictions.
   • The lack of recent top blogger opinions may indicate a lack of strong sentiment driving the stock.

In conclusion, while institutional ownership is high, the absence of strong positive sentiment indicators and the recent significant price decline suggest a neutral to slightly bearish sentiment among institutional investors regarding BTAI.